[{"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-001", "question": "A 62-year-old man develops painful hepatomegaly, ascites, and jaundice 3 weeks after completing 6 cycles of FOLFOX adjuvant chemotherapy for colon cancer. Total bilirubin is 8.2 mg/dL, ALT 450 U/L, INR 1.8. Liver biopsy shows sinusoidal congestion, hepatocyte necrosis zone 3, and absence of portal inflammation. What is the definitive therapy?", "options": ["A) High-dose methylprednisolone 1 mg/kg/day and diuretics", "B) Defibrotide 25 mg/kg/day IV in divided doses for 21 days", "C) Transjugular intrahepatic portosystemic shunt (TIPS) placement", "D) N-acetylcysteine 150 mg/kg IV bolus then continuous infusion", "E) Urgent liver transplant evaluation"], "answer": "B", "answer_index": 1, "explanation": "Severe sinusoidal obstruction syndrome from oxaliplatin requires defibrotide, which restores thrombomodulin expression and promotes fibrinolysis. TIPS is contraindicated due to diffuse sinusoidal injury; steroids are ineffective. Transplant is reserved for fulminant hepatic failure with encephalopathy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "abms_specialty": "Gastrointestinal", "abms_source": "target_topic", "source_label_raw": "Gastrointestinal", "source_quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "source_question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251221T010349114Z_kimi-k2-thinking_seed131", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251221T010349114Z_kimi-k2-thinking_seed131.jsonl", "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nClinical Presentation:\n- 62-year-old man with hepatomegaly, ascites, jaundice 3 weeks post-FOLFOX\n- Elevated bilirubin (8.2), transaminases (ALT 450), coagulopathy (INR 1.8)\n- Liver biopsy: sinusoidal congestion, zone 3 hepatocyte necrosis, NO portal inflammation\n\nKey Diagnostic Features:\nThe biopsy findings are classic for Sinusoidal Obstruction Syndrome (SOS), also known as veno-occlusive disease (VOD):\n- Sinusoidal congestion ✓\n- Zone 3 (perivenular) necrosis ✓\n- Absence of portal inflammation (rules out viral hepatitis, autoimmune) ✓\n- Timing: 3 weeks post-chemotherapy (FOLFOX is a known risk factor)\n\nSOS/VOD Pathophysiology:\n- Chemotherapy-induced endothelial injury in hepatic sinusoids\n- Results in sinusoidal obstruction and hepatic venous outflow obstruction\n- Leads to portal hypertension, ascites, and hepatic dysfunction\n\nTreatment Options Analysis:\n\nA. Methylprednisolone + diuretics - Supportive only, not definitive for SOS\n\nB. Defibrotide - This is the FDA-approved and definitive therapy for SOS/VOD. It's a polydeoxyribonucleotide that:\n   - Restores sinusoidal endothelial function\n   - Improves microcirculation\n   - Has shown efficacy in both prophylaxis and treatment of SOS\n   - Standard dose: 25 mg/kg/day IV in divided doses\n\nC. TIPS - Used for portal hypertension complications but doesn't treat underlying SOS\n\nD. N-acetylcysteine - Used for acetaminophen toxicity, not SOS\n\nE. Liver transplant - Reserved for fulminant hepatic failure; this patient may recover with defibrotide\n\nThe answer is B"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-002", "question": "A 48-year-old woman with systemic sclerosis presents with NYHA class IV dyspnea. Right heart catheterization: mPAP 52 mmHg, PAWP 6 mmHg, PVR 11 WU. Lung biopsy shows diffuse capillary proliferation within alveolar septa without cellular atypia. She fails to respond to epoprostenol and macitentan. Which intervention is associated with the greatest 5-year survival in this rare WHO Group 1' pulmonary hypertension subset?", "options": ["Switch to inhaled treprostinil 54 μg four times daily", "Add selexipag 1600 μg twice daily", "Initiate combination immunosuppression with cyclophosphamide", "Refer for bilateral lung transplantation", "Perform balloon pulmonary angioplasty"], "answer": "D", "answer_index": 3, "explanation": "Pulmonary capillary hemangiomatosis (PCH) is refractory to all PAH-targeted therapies (A, B) and immunosuppression (C). Balloon angioplasty (E) is contraindicated due to diffuse microvascular disease. Bilateral lung transplantation (D) offers the only survival benefit, with 5-year survival approaching 60% in selected patients, far exceeding the <20% survival on medical therapy alone.", "generator_model": "kimi-k2-thinking", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pulmonary", "abms_specialty": "Pulmonary", "abms_source": "topics_mapped", "source_label_raw": "pulmonology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed123", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed123-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed123", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed123.jsonl", "pred": "D", "model_outputs": "Let me analyze this case systematically.\n\nKey Clinical Features:\n- 48-year-old woman with systemic sclerosis\n- NYHA Class IV dyspnea (severe)\n- Hemodynamics: mPAP 52, PAWP 6, PVR 11 WU (elevated, consistent with pulmonary hypertension)\n- Lung biopsy: diffuse capillary proliferation without atypia\n- Failed epoprostenol and macitentan (prostacyclin and endothelin receptor antagonist)\n\nDiagnosis:\nThe biopsy finding of \"diffuse capillary proliferation within alveolar septa without cellular atypia\" is pathognomonic for pulmonary capillary hemangiomatosis (PCH), which is a WHO Group 1' pulmonary hypertension subset (rare form associated with systemic sclerosis).\n\nCritical Point:\nPCH is a rare, aggressive form of PH with poor prognosis. The key distinction is that PCH has fundamentally different pathophysiology than idiopathic PAH - it involves proliferation of capillaries rather than the typical PAH mechanism.\n\nEvaluating Options:\n\nA. Switch to inhaled treprostinil - Another prostacyclin analog; unlikely to work if epoprostenol failed\n\nB. Add selexipag - Another vasodilator; medical therapy has limited efficacy in PCH\n\nC. Initiate cyclophosphamide - Immunosuppression has been explored in PCH with some case reports of benefit, but evidence is limited\n\nD. Bilateral lung transplantation - This is the only definitive treatment for PCH. Multiple studies and case series demonstrate that lung transplantation offers the best long-term survival for PCH patients, with 5-year survival rates significantly better than medical management alone\n\nE. Balloon pulmonary angioplasty - Primarily used for chronic thromboembolic PH, not indicated for PCH\n\nAnswer:\nFor PCH (WHO Group 1'), lung transplantation is the gold standard and offers the greatest 5-year survival benefit, as medical therapies have limited efficacy in this rare subset.\n\nThe answer is D"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-003", "question": "A 55-year-old immunocompetent gardener develops subacute onset of severe headaches, focal seizures, and left hemiparesis over 3 weeks. Brain MRI shows multiple ring-enhancing lesions with surrounding edema. CSF demonstrates lymphocytic pleocytosis (120 cells/μL) but bacterial, fungal, and mycobacterial cultures are negative. What is the most appropriate empiric therapy?", "options": ["A) Liposomal amphotericin B", "B) Albendazole plus miltefosine", "C) Vancomycin plus ceftriaxone plus dexamethasone", "D) Ganciclovir plus foscarnet", "E) Voriconazole"], "answer": "B", "answer_index": 1, "explanation": "Balamuthia mandrillaris, a free-living amoeba, causes granulomatous encephalitis in immunocompetent individuals with soil exposure, presenting as ring-enhancing lesions mimicking brain abscess or tuberculosis. The combination of albendazole and miltefosine is the recommended treatment. Amphotericin B is used for Acanthamoeba, while voriconazole treats fungal infections. The antiviral combination is for CMV encephalitis.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "abms_specialty": "Infectious Disease", "abms_source": "topics_mapped", "source_label_raw": "Infectious Disease", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-009", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed124.jsonl", "pred": "B", "model_outputs": "Let me analyze this case systematically:\n\nKey Clinical Features:\n- 55-year-old immunocompetent gardener\n- Subacute onset (3 weeks) of headaches, seizures, focal neurological deficits\n- Multiple ring-enhancing lesions with edema on MRI\n- Lymphocytic pleocytosis in CSF\n- Negative bacterial, fungal, and mycobacterial cultures\n\nDifferential Diagnosis:\n\nThe ring-enhancing lesions with surrounding edema in an immunocompetent patient with subacute presentation suggests:\n\n1. Neurocysticercosis - Most likely given:\n   - Gardener (exposure to contaminated soil/food)\n   - Immunocompetent patient\n   - Ring-enhancing lesions (classic appearance)\n   - Seizures and focal deficits\n   - Lymphocytic pleocytosis\n   - Negative standard cultures\n\n2. Other considerations:\n   - Brain abscess (but cultures negative, and presentation more subacute)\n   - Toxoplasmosis (typically in immunocompromised)\n   - Fungal infection (cultures negative)\n   - Viral encephalitis (less likely with ring lesions)\n\nTreatment Options Analysis:\n\n- A) Liposomal amphotericin B - For fungal infections (cultures negative)\n- B) Albendazole plus miltefosine - Albendazole is the standard treatment for neurocysticercosis; miltefosine is used for leishmaniasis\n- C) Vancomycin plus ceftriaxone plus dexamethasone - For bacterial meningitis (cultures negative)\n- D) Ganciclovir plus foscarnet - For viral infections (less consistent with presentation)\n- E) Voriconazole - For fungal infections (cultures negative)\n\nAnswer:\nNeurocysticercosis is the most likely diagnosis in an immunocompetent gardener with ring-enhancing lesions. Albendazole is the standard antiparasitic agent for this condition. Miltefosine can be added for enhanced efficacy.\n\nThe answer is B"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-004", "question": "A 7-year-old girl with McCune-Albright syndrome (confirmed GNAS R201C mutation) presents with premature thelarche, vaginal bleeding, and a growth velocity of 12 cm/year. Bone age is 10 years. Which endocrine intervention specifically targets the underlying pathophysiology of precocious puberty in this condition?", "options": ["GnRH agonist (leuprolide) 7.5 mg IM monthly", "Aromatase inhibitor (letrozole) 2.5 mg daily", "Estrogen receptor antagonist (tamoxifen) 10 mg twice daily", "Progesterone-only contraceptive (medroxyprogesterone) 10 mg daily", "Ketoconazole 200 mg twice daily"], "answer": "B", "answer_index": 1, "explanation": "In McCune-Albright syndrome, precocious puberty results from autonomous ovarian hyperfunction, not central activation. GnRH agonists are ineffective because the process is gonadotropin-independent. Aromatase inhibitors block peripheral estrogen synthesis from autonomous follicular cysts. Tamoxifen is less effective and has more side effects. Progesterone doesn't address estrogen excess. Ketoconazole has significant toxicity.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-003", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "B", "model_outputs": "Let me work through this systematically.\n\nUnderstanding McCune-Albright Syndrome (MAS):\n- Caused by GNAS R201C mutation (constitutively active Gs alpha protein)\n- Results in autonomous cAMP production independent of hormone stimulation\n- Causes autonomous ovarian follicle development and estrogen production\n- This is NOT GnRH-dependent precocious puberty\n\nKey Pathophysiology:\nIn MAS, the ovaries produce estrogen autonomously due to constitutive activation of the cAMP pathway. This is peripheral/autonomous precocious puberty, NOT central (GnRH-dependent) precocious puberty.\n\nAnalyzing Each Option:\n\nA. GnRH agonist (leuprolide):\n- Works by suppressing GnRH-dependent puberty\n- In MAS, puberty is NOT GnRH-dependent but autonomous\n- Would NOT be effective for the underlying pathophysiology\n- May even cause rebound effect when stopped\n\nB. Aromatase inhibitor (letrozole):\n- Blocks conversion of androgens to estrogen\n- Directly targets the excessive estrogen production\n- Reduces circulating estrogen levels\n- Addresses the actual pathophysiology (autonomous estrogen production)\n- This is the preferred treatment for MAS precocious puberty\n\nC. Estrogen receptor antagonist (tamoxifen):\n- Blocks estrogen receptors\n- Can be used but less preferred than aromatase inhibitors\n- May have more side effects\n\nD. Medroxyprogesterone:\n- Can slow growth and bone maturation\n- Not specifically targeting the underlying pathophysiology\n\nE. Ketoconazole:\n- Inhibits steroidogenesis\n- Not the primary targeted approach\n\nThe answer is B"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-005", "question": "A 35-year-old presents with refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g of sustained-release verapamil. High-dose insulin euglycemic therapy (HIET) is initiated. What is the optimal insulin dosing and monitoring frequency?", "options": ["0.5-1 unit/kg/hr; check glucose every 2 hours", "1-10 units/kg/hr; check glucose every hour", "0.1-0.5 units/kg/hr; check potassium every 4 hours", "5-20 units/kg/hr; check lactate every 2 hours", "2-5 units/kg/hr; check pH every 4 hours"], "answer": "B", "answer_index": 1, "explanation": "HIET for severe calcium channel blocker overdose requires supraphysiologic insulin doses of 1-10 units/kg/hr to overcome insulin resistance and maximize myocardial glucose uptake. Blood glucose must be monitored hourly to maintain euglycemia (150-200 mg/dL) with concurrent dextrose infusion. Lower doses are ineffective. Doses exceeding 10 units/kg/hr are not standard practice. Potassium and pH are monitored but glucose is the critical parameter.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Emergency Medicine", "abms_specialty": "Emergency Medicine", "abms_source": "topics_mapped", "source_label_raw": "Emergency Medicine", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-008", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed125", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed125.jsonl", "pred": "B", "model_outputs": "Looking at this calcium channel blocker (verapamil) overdose case with refractory shock, I need to identify the correct high-dose insulin euglycemic therapy (HIET) protocol.\n\nKey considerations for HIET in verapamil toxicity:\n\nInsulin Dosing:\n- Standard HIET protocols use an initial bolus of 1 unit/kg IV followed by continuous infusion\n- The infusion rate typically starts at 0.5-1 unit/kg/hr and can be titrated up to 10 units/kg/hr based on hemodynamic response\n- This patient has refractory shock, so higher doses within the therapeutic range may be needed\n- Option B (1-10 units/kg/hr) represents the appropriate infusion range\n\nMonitoring Requirements:\n- Glucose: Must be checked frequently (every 15-30 minutes initially, then every 1-2 hours) because:\n  - Insulin causes hypoglycemia\n  - Dextrose must be co-infused to maintain euglycemia (100-250 mg/dL)\n  - This is the primary safety concern with HIET\n  \n- Potassium: Critical to monitor (every 1-2 hours) because:\n  - Insulin drives potassium intracellularly\n  - Severe hypokalemia can develop and worsen cardiac dysrhythmias\n  - This is especially dangerous in a patient with bradycardia from calcium channel blocker toxicity\n\nAnalysis of options:\n- A: Dose too low for refractory shock\n- B: Correct dose range (1-10 units/kg/hr) with hourly glucose checks ✓\n- C: Dose too low; potassium monitoring alone is insufficient\n- D: Lactate monitoring is not the primary concern\n- E: pH monitoring is not the primary concern\n\nOption B provides both the appropriate insulin dosing range for refractory shock and the critical glucose monitoring frequency needed to prevent hypoglycemia.\n\nThe answer is B"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-006", "question": "A 30-year-old G2P1 at 32 weeks gestation presents with fetal hydrops and mirror syndrome. Which pathophysiologic mechanism best explains her severe preeclampsia-like features?", "options": ["Massive fetomaternal hemorrhage causing maternal anemia", "Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1)", "Maternal antibody production against fetal Rh antigens", "Amniotic fluid embolism triggering systemic inflammation", "Mirror syndrome is a misdiagnosis; this is atypical HELLP"], "answer": "B", "answer_index": 1, "explanation": "Mirror syndrome involves placental edema that mechanically compromises uteroplacental perfusion and releases anti-angiogenic factors like sFlt-1, creating a preeclampsia phenotype. Resolution occurs within 48 hours of delivery or fetal therapy that reduces hydrops.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Obstetrics and Gynecology", "abms_specialty": "Obstetrics and Gynecology", "abms_source": "topics_mapped", "source_label_raw": "obstetrics", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-005", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed126", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed126.jsonl", "pred": "B", "model_outputs": "Let me work through this systematically.\n\nThe question describes:\n- 32 weeks gestation\n- Fetal hydrops\n- Mirror syndrome (maternal preeclampsia-like features that mirror fetal pathology)\n- Severe preeclampsia-like features in the mother\n\nMirror syndrome is a real clinical entity where maternal preeclampsia-like symptoms develop in association with fetal hydrops. The key is understanding the pathophysiology.\n\nLet me evaluate each option:\n\nA. Massive fetomaternal hemorrhage causing maternal anemia\n- This would cause anemia but doesn't explain the preeclampsia-like features (hypertension, proteinuria, edema)\n\nB. Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1)\n- sFlt-1 is an antiangiogenic factor that causes endothelial dysfunction\n- In preeclampsia, elevated sFlt-1 causes the characteristic features: hypertension, proteinuria, edema\n- Placental edema (which occurs with fetal hydrops) can increase sFlt-1 release\n- This mechanism explains how fetal pathology (hydrops) leads to maternal preeclampsia-like syndrome\n- This is the established pathophysiologic mechanism for mirror syndrome\n\nC. Maternal antibody production against fetal Rh antigens\n- This causes hemolytic disease of the fetus, which can lead to hydrops\n- But doesn't explain the maternal preeclampsia-like features\n\nD. Amniotic fluid embolism\n- This is an acute, catastrophic event, not a chronic condition at 32 weeks\n- Doesn't fit the clinical presentation\n\nE. Mirror syndrome is a misdiagnosis\n- Mirror syndrome is a recognized clinical entity, not a misdiagnosis\n\nThe best answer is B - the placental edema associated with fetal hydrops releases sFlt-1, which causes endothelial dysfunction and the maternal preeclampsia-like syndrome characteristic of mirror syndrome.\n\nThe answer is B"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-007", "question": "A 35-year-old male in a personal injury lawsuit reports severe chronic pain despite normal examinations and imaging. He is observed to be inconsistent in his symptom presentation between evaluations. Which specific criterion best distinguishes malingering from factitious disorder in this scenario?", "options": ["Presence of secondary gain", "Intentional production of symptoms", "Lack of insight into psychological factors", "Symptoms are under voluntary control", "Absence of medical explanation"], "answer": "A", "answer_index": 0, "explanation": "Both malingering and factitious disorder involve intentional symptom production. The key distinction is motivation: malingering seeks external reward (money, avoiding work), while factitious disorder seeks the 'sick role' for psychological needs. Both have insight and voluntary control. Absence of medical explanation is common to both somatic symptom disorders.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Psychiatry", "abms_specialty": "Psychiatry", "abms_source": "target_topic", "source_label_raw": "Psychiatry", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-020", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "A", "model_outputs": "To distinguish between malingering and factitious disorder, I need to consider the key differentiating features:\n\nMalingering:\n- Intentional production of false/exaggerated symptoms\n- External motivation (secondary gain) - seeking tangible rewards like money, avoiding work, legal benefits\n- Conscious and deliberate deception\n- Symptoms stop when the incentive is removed\n\nFactitious Disorder:\n- Intentional production of false/exaggerated symptoms\n- Internal motivation - psychological need to assume sick role, attention-seeking without external reward\n- Conscious deception but driven by psychological factors\n- Symptoms continue even without external gain\n\nNow analyzing the options:\n\nA. Presence of secondary gain - This is the KEY distinguishing feature. The patient is in a personal injury lawsuit (clear external incentive/secondary gain), which points toward malingering rather than factitious disorder.\n\nB. Intentional production of symptoms - Both conditions involve intentional production, so this doesn't distinguish them.\n\nC. Lack of insight into psychological factors - Not the primary distinguishing criterion.\n\nD. Symptoms are under voluntary control - Both involve voluntary control of symptoms.\n\nE. Absence of medical explanation - Both can present with normal findings.\n\nThe critical distinction is the presence of secondary gain (external motivation like money/legal benefits in a lawsuit), which characterizes malingering and differentiates it from factitious disorder (which lacks external motivation).\n\nThe answer is A"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-008", "question": "A 68-year-old man presents with a 2-year history of progressive sleep dysfunction characterized by dream enactment, nocturnal stridor, and daytime somnolence. He has developed gait instability and mild cognitive decline. Polysomnography reveals non-REM parasomnias and REM sleep behavior disorder. CSF studies are normal, and brain MRI shows mild cerebellar atrophy. Which antibody is most likely associated with this syndrome?", "options": ["A) Anti-Hu antibody", "B) Anti-Yo antibody", "C) Anti-IgLON5 antibody", "D) Anti-Ma2 antibody", "E) Anti-NMDA receptor antibody"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease is a tauopathy characterized by severe sleep dysfunction (non-REM parasomnias, REM behavior disorder), bulbar symptoms, gait instability, and cognitive decline, often with normal CSF and nonspecific MRI findings. Anti-Hu and Anti-Yo are associated with limbic encephalitis and paraneoplastic cerebellar degeneration respectively. Anti-Ma2 causes diencephalic syndrome, and anti-NMDA receptor encephalitis presents with psychiatric symptoms and characteristic CSF abnormalities.", "generator_model": "kimi-k2-thinking", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Neurology", "abms_specialty": "Neurology", "abms_source": "topics_mapped", "source_label_raw": "Neurology", "source_quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed124", "source_question_id": "20251205T080918850Z_kimi-k2-thinking_seed124-001", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251205T080918850Z_kimi-k2-thinking_seed124", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026_backup/20251205T080918850Z_kimi-k2-thinking_seed124.jsonl", "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nKey Clinical Features:\n1. 68-year-old man\n2. Progressive sleep dysfunction (2-year history)\n3. Dream enactment (REM sleep behavior disorder)\n4. Nocturnal stridor\n5. Daytime somnolence\n6. Gait instability\n7. Mild cognitive decline\n8. Polysomnography: non-REM parasomnias and REM sleep behavior disorder\n9. Normal CSF\n10. Mild cerebellar atrophy on MRI\n\nAnalysis of Each Option:\n\nA) Anti-Hu antibody: Associated with small cell lung cancer and paraneoplastic neurological syndromes, but typically causes encephalomyelitis, sensory neuropathy, or cerebellar degeneration. Not specifically associated with sleep disorders and REM behavior disorder.\n\nB) Anti-Yo antibody: Associated with paraneoplastic cerebellar degeneration in ovarian and breast cancer. Causes ataxia and cerebellar signs but not the characteristic sleep dysfunction described.\n\nC) Anti-IgLON5 antibody: This is a relatively recently recognized antibody associated with a distinctive syndrome featuring:\n- Sleep disorders (REM and non-REM parasomnias)\n- REM sleep behavior disorder\n- Nocturnal stridor\n- Gait instability\n- Cognitive decline\n- Cerebellar atrophy\n- Often has NORMAL CSF (which matches this case)\n- Typically affects older adults\n\nThis matches the clinical presentation perfectly.\n\nD) Anti-Ma2 antibody: Associated with limbic encephalitis, brainstem encephalitis, and cerebellar atrophy, but not characteristically with REM sleep behavior disorder and nocturnal stridor.\n\nE) Anti-NMDA receptor antibody: Causes psychiatric symptoms, seizures, movement disorders, and autonomic instability, but not the specific sleep parasomnia pattern described.\n\nThe combination of REM sleep behavior disorder, nocturnal stridor, non-REM parasomnias, gait instability, cognitive decline, cerebellar atrophy, and normal CSF is pathognomonic for anti-IgLON5 antibody-associated neurological disorder.\n\nThe answer is C"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-009", "question": "A 2-month-old infant with congenital lymphocytic choriomeningitis virus (LCMV) infection presents with chorioretinitis, hydrocephalus, and periventricular calcifications. Which neuroimaging finding best distinguishes LCMV from congenital cytomegalovirus infection?", "options": ["Periventricular calcifications", "Cortical malformations", "Cerebellar hypoplasia", "Temporal lobe cysts", "Lissencephaly"], "answer": "C", "answer_index": 2, "explanation": "While both LCMV and CMV can cause periventricular calcifications, LCMV characteristically causes severe cerebellar hypoplasia due to selective infection of the external granular layer cells. CMV more commonly causes cortical malformations, temporal lobe cysts, and lissencephaly. This distinction is critical for prognosis and genetic counseling, as LCMV has a higher risk of severe neurodevelopmental disability.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-004", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "C", "model_outputs": "To answer this question, I need to compare the neuroimaging findings of congenital LCMV versus congenital CMV infection.\n\nCongenital LCMV findings:\n- Periventricular calcifications\n- Hydrocephalus\n- Chorioretinitis\n- Cerebellar hypoplasia (characteristic finding)\n- Microcephaly\n\nCongenital CMV findings:\n- Periventricular calcifications (common)\n- Ventriculomegaly/hydrocephalus\n- Cortical malformations (polymicrogyria, schizencephaly)\n- Lissencephaly\n- Temporal lobe cysts\n- Microcephaly\n\nAnalysis of options:\n\nA. Periventricular calcifications - Present in BOTH conditions, so not distinguishing\n\nB. Cortical malformations - More characteristic of CMV (polymicrogyria, schizencephaly), not typical of LCMV\n\nC. Cerebellar hypoplasia - This is a CHARACTERISTIC and DISTINGUISHING finding of congenital LCMV. While CMV can affect the cerebellum, cerebellar hypoplasia is particularly associated with LCMV.\n\nD. Temporal lobe cysts - More characteristic of CMV infection\n\nE. Lissencephaly - More characteristic of CMV infection\n\nThe key distinguishing feature of congenital LCMV is cerebellar hypoplasia, which is a hallmark finding that helps differentiate it from congenital CMV, which more typically presents with cortical malformations and temporal lobe involvement.\n\nThe answer is C"}, {"quiz_id": "ABMS20260101_kimi-k2-thinking_p05", "question_id": "ABMS20260101_kimi-k2-thinking_p05-010", "question": "A 2-month-old infant presents with heart failure, mitral regurgitation, and echocardiographic finding of retrograde flow in a dilated left coronary artery during diastole. Which additional echocardiographic finding is pathognomonic for anomalous left coronary artery from pulmonary artery (ALCAPA)?", "options": ["Left ventricular dilation", "Papillary muscle dysfunction", "Septal wall motion abnormalities", "Coronary artery collaterals with 'seagull' sign", "Right coronary artery dilation"], "answer": "D", "answer_index": 3, "explanation": "In ALCAPA, extensive intercoronary collaterals develop with characteristic bidirectional flow seen on color Doppler as a 'seagull' sign. While LV dilation, papillary muscle dysfunction, and RCA dilation are seen, they are not pathognomonic. The seagull sign represents collaterals from RCA to LCA with flow reversal into PA, which is diagnostic of ALCAPA.", "generator_model": "kimi-k2-thinking", "seed": 128, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Pediatrics", "abms_specialty": "Pediatrics", "abms_source": "target_topic", "source_label_raw": "Pediatrics", "source_quiz_id": "20251219T234603131Z_kimi-k2-thinking_seed128", "source_question_id": "20251219T234603131Z_kimi-k2-thinking_seed128-013", "source_runs_root": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs", "source_run_dir": "/home/dbernardo/Documents/pyres/MedEvalArena/eval_results/quizbench/quizzes_Jan2026/runs/kimi-k2-thinking/20251219T234603131Z_kimi-k2-thinking_seed128", "source_quiz_path": "/home/dbernardo/Documents/pyres/MedEvalArena/quizzes/quizzes_Jan2026/20251219T234603131Z_kimi-k2-thinking_seed128.jsonl", "pred": "D", "model_outputs": "Let me work through this systematically.\n\nThe clinical presentation describes:\n- 2-month-old infant\n- Heart failure\n- Mitral regurgitation\n- Retrograde flow in dilated left coronary artery during diastole\n\nThis is consistent with ALCAPA (Anomalous Left Coronary Artery from Pulmonary Artery).\n\nIn ALCAPA:\n- The left coronary artery originates from the pulmonary artery instead of the aorta\n- During diastole, when pulmonary artery pressure drops below aortic pressure, blood flows retrograde from the left coronary artery back into the pulmonary artery (coronary steal)\n- This causes myocardial ischemia, particularly affecting the left ventricle\n- The right coronary artery (which originates normally from the aorta) develops extensive collaterals to supply the left coronary territory\n\nNow let's evaluate the pathognomonic finding:\n\nA. Left ventricular dilation - This is a consequence of ischemia, not pathognomonic\nB. Papillary muscle dysfunction - This is a consequence of ischemia, not pathognomonic\nC. Septal wall motion abnormalities - This is a consequence of ischemia, not pathognomonic\nD. Coronary artery collaterals with 'seagull' sign - The \"seagull sign\" refers to the appearance of dilated right coronary artery with extensive collaterals creating a characteristic pattern. This is the pathognomonic echocardiographic finding of ALCAPA\nE. Right coronary artery dilation - While the RCA is dilated, this alone isn't pathognomonic\n\nThe \"seagull sign\" (or \"bird's nest\" appearance) represents the dilated right coronary artery with extensive collateral circulation, which is the characteristic and pathognomonic finding in ALCAPA.\n\nThe answer is D"}]